Zions’ first quarter results were impacted by an $0.11 per share charge to income tax expense due to a Utah tax law change affecting securities portfolio income. The company noted that most of this ...

Novo Nordisk (NYSE: NVO) has filed for U.S. approval of an oral version of its blockbuster weight loss drug Wegovy, the company confirmed to BioPharma Dive. The Danish drugmaker disclosed the ...